Following the EMA’s approval in late 2017, the FDA has now also approved Lutathera (lutetium Lu 177 dotatate) for certain digestive tract cancers.

The potential of neuroprotective agents for a whole new form of treatment.

A list of medicines TheSocialMedwork will soon be making available.

New test detects ovarian and 7 other cancers using simple blood sample.

Brentuximab vedotin (Adcetris) has now been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) who have had at least 1 prior systemic therapy.

Lynparza (olaparib) is the first PARP inhibitor approved to treat breast cancer, and the first medicine ever for metastatic breast cancer who have a “BRCA” gene mutation.

Ocrevus (ocrelizumab), the first ever FDA approved medicine for primary progressive MS has now also been approved by the EMA.

A new study found that cabozantinib (Cabometyx) was more effective than everolimus in advanced renal cell carcinoma and bone metastases.

Pembrolizumab showed positive results in heavily pretreated, PD-L1–positive advanced esophageal carcinoma.

Specific strains of intestinal bacteria can improve the response rate to immunotherapy for patients being treated for advanced melanoma.

Eight important updates in lung cancer.

Darzalex (daratumumab) combination under review as first-line option.

Immunotherapy nivolumab has been linked to HIV reservoir decrease in a lung cancer patient. 

In a pilot study immunotherapy proved active in some patients with metastatic, trastuzumab (Herceptin)-resistant HER2-positive breast cancer.

Is there substance to the claims that it's a groundbreaking treatment?

Researchers are suggesting that metastatic tumours in the lung can be successfully eradicated using cryotherapy – literally turning the masses into ice balls that are then resorbed by the body.

The FDA has approved the first biosimilar for the treatment of certain breast and stomach cancers.

Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).

A phase 3 study on lung cancer showed that Imfinzi (durvalumab) as a consolidation therapy reduced the risk of the disease progressing by 48 percent.

FDA approves Juluca (dolutegravir and rilpivirine) for the maintenance treatment of certain patients with HIV-1 infection.

Introducing a breakthrough known as 'CT1812'

Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.

As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.

With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.

PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.

What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?

For the first time in 22 years, the US Food and Drug Administration (FDA) has approved a drug to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease; a motor neuron disease characterised by muscular atrophy and weakness.

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment

The PBS, Australia’s national program responsible for providing subsidised prescriptions, has announced the addition of several new medicines

Promising Results from Multiple Studies